Highlights Ipsen

Equities

IPN

FR0010259150

Market Closed - Euronext Paris Other stock markets 16:35:19 08/05/2024 BST			5-day change	1st Jan Change
116.8 ^EUR	+1.39%		+2.37%	+8.25%

05-02	Ipsen Announces Executive Changes	CI
05-02	Ipsen: new President for North America	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IPSEN : Better-than-expected Q1; guidance unchanged	04-24
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	04-22	MT
Ipsen: collaboration agreement with Skyhawk	04-22	CF
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	04-22	CI
Ipsen: worldwide licensing agreement with Sutro Biopharma	04-02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	04-02	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	03-13
Ipsen: new indication approved in pancreatic cancer	02-14	CF
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	02-13	DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	02-13	CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	02-08
Ipsen: 13% drop in annual EPS	02-08	CF
Ipsen presents positive data for Cabometyx	01-23	CF
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024	01-22	CI
Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC	12-07	CI
Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial	11-13	CI
Ipsen S.A. Confirms Sales Guidance for the Fiscal Year 2023	26/10/23	CI
Tribal Group recommends GBP172 million takeover from Ellucian	05/10/23	AN
Ipsen Updates on QM-1114 Regulatory Process	03/10/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 03:50 pm